Metastatic Colorectal Cancer: Patient Presentation, Diagnosis, and Treatment

Opinion
Video

Comprehensive insights on the stratification, diagnosis, and treatment of patients with metastatic colorectal cancer.

This is a synopsis of an Insights series featuring Marwan G. Fakih, MD, of City of Hope, and Atif Hussein, MD, MMM, FACP, of Memorial Healthcare System.

Dr Fakih asked Dr Hussein whether he has observed changes in patients with colorectal cancer (CRC) seen in his oncology practice. Dr. Hussein confirmed seeing younger patients with CRC, likely related to delayed screening during the COVID-19 pandemic, resulting in more patients presenting with advanced disease. He emphasized that colonoscopy allows early detection and removal of precancerous polyps, distinguishing it from purely diagnostic screening tests. Still, at diagnosis 50% of patients have metastatic disease, some even with unusual bone metastases. Until colonoscopy uptake reaches 80% to 90% like mammography, metastatic CRC will remain highly prevalent. Patients often first report abdominal discomfort, rectal bleeding, or iron deficiency anemia to primary care, ultimately leading to a CRC diagnosis.

For metastatic CRC, Dr Hussein obtains next generation sequencing, assessing RAS mutation status to guide first-line anti-epidermal growth factor receptor therapy eligibility. Other tested markers include microsatellite instability, BRAF mutations, and HER2 amplifications, most relevant after first-line treatment. Left-sided tumors, more addicted to epidermal growth factor receptor, respond better to cetuximab or panitumumab with chemotherapy. Right-sided tumors are treated with bevacizumab and chemotherapy. After exhausting the 2 standard lines of therapy, few third-line options exist, underscoring the need Dr Hussein cited for research like the phase 2 SUNLIGHT trial evaluating trifluridine/tipiracil and bevacizumab in this refractory setting.

Dr Fakih agreed, noting rationale for sidedness-guided treatment based on biological differences between right and left colon embryonic origins. Both emphasized PARP analysis at diagnosis along with sidedness and RAS mutation status to personalize metastatic CRC treatment while awaiting improved screening penetration to reduce advanced disease prevalence.

*Video synopsis is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content